Roland Diggelmann - Smith Nephew Chief Executive Officer, Executive Director
SNN Stock | USD 25.36 0.98 3.72% |
CEO
Mr. Roland Diggelmann is NonExecutive Independent Director of the Company since 1 March 2018. He was elected by shareholders at the AGM on 12 April 2018. He will join the Compliance Culture Committee in April 2019. Career and experience Roland studied Business Administration at the University of Berne. In 1995, he joined Sulzer AG as Manager Strategic Planning and progressed into further senior roles over the years until his appointment as Executive Vice President, Sales Europe and Asia Pacific from 2002 to 2004 for Sulzer Medica . Roland joined Zimmer Group in 2004, in the role of Managing Director of Zimmer Japan and then later in 2006 as Senior Vice President, EMEA until 2008. Roland joined Roche Diagnostics in 2008 starting as president of Asia Pacific before assuming the role of Chief Executive Officer of the Diagnostics Division of F. HoffmannLa Roche Ltd from 2012 until September 2018. Skills and competencies Having spent his whole career in medical devices, with 12 years at Sulzer and Zimmer, Roland brings an indepth knowledge of the medical device industry and healthcare environment which is of great value to Smith Nephew. since 2019.
Age | 53 |
Tenure | 5 years |
Address | Building 5, Watford, United Kingdom, WD18 8YE |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has Return on Asset of 0.0427 % which means that on every $100 spent on assets, it made $0.0427 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0502 %, implying that it generated $0.0502 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Capital Employed is likely to drop to 0.12. In addition to that, Return On Assets is likely to drop to 0.03. At this time, Smith Nephew's Total Assets are very stable compared to the past year. As of the 29th of March 2024, Non Current Assets Total is likely to grow to about 6.3 B, while Other Current Assets are likely to drop about 87.4 M.Similar Executives
Found 4 records | CEO Age | ||
John Mastrototaro | Movano Inc | 63 | |
Mark Pomeranz | Motus GI Holdings | 62 | |
Timothy Moran | Motus GI Holdings | 52 | |
Christopher Rowland | Medigus Ltd ADR | 56 |
Management Performance
Return On Equity | 0.0502 | ||||
Return On Asset | 0.0427 |
Smith Nephew SNATS Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Friedman, Non-Executive Independent Director | ||
Helen Barraclough, Company Counsel | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Chief Executive Officer, Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Independent Director | ||
Simon Fraser, President - Advanced Wound Management and Global Commercial Operations | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, Chief Financial Officer, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Ian Melling, Interim Chief Financial Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, Senior Communications | ||
Rick Medlock, Non-Executive Independent Director | ||
Glenn Warner, President - Advanced Wound Management | ||
Paul Connolly, President Operations | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Independent Director | ||
Mark Gladwell, President - Global Operations and Global Business Services | ||
John Ma, Non-Executive Independent Director | ||
Vasant Padmanabhan, President - Research & Development | ||
Joseph Papa, Non-Executive Independent Director | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Ian Barlow, Non-Executive Independent Director | ||
Namal Nawana, Chief Executive Officer, Executive Director | ||
Bob White, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Independent Director | ||
Deepak Nath, Chief Executive Officer | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Independent Director | ||
AnneFrancoise Nesmes, Chief Financial Officer, Executive Director | ||
Rodrigo Bianchi, Interim President - Asia Pacific | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, President Orthopaedics | ||
Katarzyna MazurHofsaess, Non-Executive Independent Director | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Peter Coenen, President - EMEA Region | ||
Robin Freestone, Senior Non-Executive Independent Director | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Myra Eskes, President - Asia Pacific | ||
Andrew Swift, Vice Relations | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Ingeborg Oie, VP, Investor Relations | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President - Sports Medicine & ENT | ||
Jo Hallas, Non-Executive Director | ||
Catheryn ORourke, Chief Legal and Compliance Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0502 | ||||
Return On Asset | 0.0427 | ||||
Profit Margin | 0.05 % | ||||
Operating Margin | 0.14 % | ||||
Current Valuation | 14.3 B | ||||
Shares Outstanding | 437.16 M | ||||
Shares Owned By Insiders | 0.03 % | ||||
Shares Owned By Institutions | 7.58 % | ||||
Number Of Shares Shorted | 2.22 M | ||||
Price To Earning | 25.42 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.
Currently Active Assets on Macroaxis
When determining whether Smith Nephew SNATS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Smith Nephew's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Smith Nephew Snats Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Smith Nephew Snats Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Smith Stock analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
CEOs Directory Screen CEOs from public companies around the world | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Commodity Directory Find actively traded commodities issued by global exchanges |
Is Smith Nephew's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.983 | Dividend Share 0.375 | Earnings Share 0.6 | Revenue Per Share 2.5484 | Quarterly Revenue Growth 0.076 |
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.